Business Wire

The Engaged Database (TED), a Benchmark Sample of Anonymised Clinical Study Audit Observations, Compiled According to EMA Inspection Database Categories.

Jaa

The Engaged Database (TED) allows users to compare their own audit observations, against a large number of other audit results, grouped according to the European Medicines Agency (EMA) categories and sub-categories and classification criteria. The data is fully anonymised using a numbering system for each audit, protecting the identity of the auditor/auditee.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180312005535/en/

TED reports plot user audit observations against other benchmark audit results of the same audit type, already in the database. In addition, the report shows the percentage of audit reports with findings in this category and gives an average compliance index of the severity of observations. Filters such as clinical phase, geographical location, or a specific observation, can be used to tailor the benchmark sample further. This provides a global resource for all pharmaceutical, biotechnology and medical device companies, as well as academia. Users can see in no time where their audit result stands, compared to a larger volume of audit results already entered.

TED is owned and managed by Dr. Barbara Heumann, who owns the independent auditing company, GXP Engaged Auditing Services. TED has a governance group made up of clinical research professionals, from all over the world, who ensure that the process to collect and capture audit data is sound and based upon robust quality criteria and in full compliance with scientific, legal and ethical standards.

TED is a smart solution saving resources and helping to avoid research and development project failures by allowing users to find out early how their audit programme measures up against those of other companies. What do the results really mean and what can one learn from them?

Speaking at the recent launch of The Engaged Database (TED), Dr. Barbara Heumann said, “TED can help large companies avoid a bias when interpreting audit results, whilst allowing smaller companies to benchmark even if they have only very few audits of one type. Therefore, potential risks can be identified which can lead to a more informed decision on a corporate level.” She summed up by saying, “We will be exhibiting TED at SQA 8-13 April, DIA Europe 17-19 April, DIA China 23-25 May and DIA Boston 24-28 June and we look forward to demonstrating and promoting this excellent tool with you there, as well as within our sponsor networks worldwide.”

Contact information

The Engaged Database GmbH
Dr. Barbara Heumann
Email: info@TheEngagedDB.com
Telephone: 0049 (0)89 93003897
www.TheEngagedDB.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

ResMed’s First Top-of-Head CPAP Mask, AirFit N30i, Now Available across U.S.21.1.2019 17:05Tiedote

ResMed (NYSE: RMD, ASX: RMD), today introduced AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the United States, with a newly designed nasal cradle cushion that sits just under the wearer’s nose. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005035/en/ AirFit N30i nasal CPAP mask, front view (Photo: Business Wire) The top-of-head connection keeps tubing out of the wearer’s way, letting them move and sleep in any position. The nasal cradle cushion – ResMed’s first – is designed to reduce facial markings and irritation. AirFit N30i is also convenient for equipment providers and sleep labs – it fits 96 percent of PAP users with just two frame sizes and four cushion sizes. How AirFit N30i compares to the market-leading nasal top-of-head mask In side-by-side comparisons, three out of four users preferred AirFit N30i over the other nasal mask with a top-of-head connection. A majority stated they loved

Metabolon Appoints Michael Rasche as President of International Business21.1.2019 16:06Tiedote

Metabolon, the world leader in metabolomics, today announced that Michael Rasche joined the company as President of International Business. Michael will report to Rohan Hastie, Metabolon’s President and CEO, and become a member of the corporate executive team. He will lead all of Metabolon's international business activities with a strong focus on customer and team expansion. "We are thrilled to have Michael join the Metabolon team," said Hastie. "Michael brings a wealth of commercial and business experience across multiple areas of life sciences, from Pharma to Diagnostics and Biotech. I know he will make an immediate impact on our existing and future customers." "I am very excited to become part of the Metabolon success story," added Rasche. "I will passionately lead our team to drive accelerated business expansion across all international markets. Our Precision Metabolomics™ technology is delivering biomarker discoveries, innovative diagnostic tests, and groundbreaking data in genom

AMCS Announces Acquisition of Recy Systems21.1.2019 16:00Tiedote

AMCS, the world’s leading supplier of integrated software and vehicle technology for the waste and recycling sector, has today announced the acquisition of Germany's leading recycling and waste management software specialist, Recy Systems (Recy). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005193/en/ Recy has offices in Germany, U.S., U.K. and Slovakia. Their customers include some of the world’s largest and most complex recycling companies. Overall, the acquisition will add another 600 customers from across Europe, in North America, Asia, and Africa, taking AMCS’ total customer base to over 2400 worldwide. In addition to growing AMCS’ market share in the high-growth German market, the acquisition will support its continued development of a best-in-class global solution for the metal recycling industry. It will also contribute to the development of the company’s platform used by the wider waste, recycling and resour

Anticipation Builds as MWC19 Barcelona Approaches21.1.2019 12:00Tiedote

The GSMA today announced final updates for MWC19 Barcelona (formerly Mobile World Congress), including additional keynote speakers, participating companies, programmes and events. Taking place 25-28 February 2019, with events being staged at Fira Gran Via, Fira Montjuïc and La Farga L’Hospitalet, MWC19 Barcelona is set to attract more than 107,000 professionals from over 200 countries and territories. “With the anticipated arrival of 5G, this year’s event is set to be one of the most exciting as the industry convenes to showcase Intelligent Connectivity across new technologies on the brink of reaching millions of people across the world,” said John Hoffman, CEO, GSMA Ltd. “Over the four days of MWC19, attendees will have the opportunity to hear from leaders who are driving innovation and we look forward once again to welcoming the mobile world to Barcelona.” Global Leaders to Keynote The GSMA announced the addition of several new keynote speakers for MWC19 including executives from lea

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease21.1.2019 12:00Tiedote

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. “Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. ‘‘By treating the underlying cause of disease early, we can potentially modify its course and offer patients the chance of improved outcomes.’’ The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with

B2C2 Launches Streaming OTC Pricing with Point-and-Click Execution21.1.2019 12:00Tiedote

B2C2, one of the largest cryptocurrency liquidity providers and the leader in electronic OTC trading, today announced the launch of streaming pricing with point-and-click execution on its OTC platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005063/en/ Max Boonen, Founder and CEO of B2C2 (Photo: Business Wire) For the first time, B2C2’s clients will be able to view and execute trades on a real-time two-way market, via the firm’s secure web interface. The new functionality allows market participants to easily monitor live pricing in user-defined quantities and execute with the click of a button, as they would on traditional FX trading platforms. The launch rounds out a number of milestones for B2C2 in 2018, including surpassing 2017 peak volumes; rolling out a completely redesigned front-end; forming integration partnerships with the major liquidity hubs; and launching a research offering. Founded in 2015, B2C2 i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme